GlassScriptPhysician profile
Leonard M Flescher
NPI 1982660262
$3,158.74
in general payments reported to CMS, 2019-2025
28 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $74.74 · 2021: $251 · 2022: $388 · 2023: $888 · 2024: $403 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $861.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.46 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $365.02 | 2022-2025 | Entyvio, Eohilia |
| Celgene Corporation | $179.93 | 2021-2023 | Zeposia |
| Allergan, INC. | $173.44 | 2019 | |
| Janssen Biotech, INC. | $154.82 | 2021-2025 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $134.12 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $109.54 | 2022-2023 | Dificid |
| Covidien LP | $92.68 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $72.66 | 2021-2023 | Kristalose |
| Regeneron Healthcare Solutions, INC. | $66.11 | 2025 | Dupixent |
| Gilead Sciences, INC. | $66.08 | 2021-2025 | |
| Lilly USA, LLC | $49.82 | 2023 | |
| Pfizer INC. | $49.67 | 2024-2025 | |
| Ardelyx, INC. | $45.85 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $44.48 | 2019 | |
| Romark Laboratories, Lc | $42.77 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.92 | 2025 | Cabtreo |
| Fujifilm Healthcare Americas Corporation | $35.86 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.14 | 2025 | Voquezna |
| Redhill Biopharma INC. | $24.75 | 2021 | |
| Novo Nordisk INC | $21.60 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $19.88 | 2023 | Linzess |
| Bausch Health US, LLC | $17.20 | 2025 | Wellbutrin |
| Alfasigma USA, INC. | $15.34 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $13.12 | 2022 | |
| Cook Medical LLC | $11.31 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Flescher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.